Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation

Abstract

Recent progress in translational neuroscience has significantly advanced our understanding of neurological diseases. Research progress closely went in line with innovations in research methods, which have expanded our insights considerably beyond previous limits. However, despite the development of disease-modifying treatments, therapeutic options in brain diseases still lag behind fundamental discoveries in basic neuroscience. This perspective examines the factors that hinder clinical progress in translational neuroscience and provides solutions on how to overcome them. Editorial board members of Exploration of Neuroscience were interrogated about the most prominent challenges they see in translational neuroscience and about possible ways to overcome these issues. Key challenges were seen at the interface between experimental research and clinical studies by several members, both from the basic and applied neuroscience fields, which include the selection of appropriate study readouts and endpoints. The establishment of refined study endpoints, combined with biomarkers capable of predicting treatment responses in human patients, will be crucial for the successful clinical implementation of new therapies. Further obstacles were found in the standardization of experimental models, interventions, and assessments both in animals and humans, as well as in the development of personalized treatment strategies. These challenges can be addressed through more clearly defined experimental procedures that closely match clinical conditions and precision-based approaches that ensure efficient therapeutic responses. As a great opportunity, treatment options targeting pathophysiological processes in multiple brain diseases and disease processes in different organ systems were noted. Significant barriers remain in the funding of investigator-driven clinical trials through public research programs, as well as the education of translational and clinician scientists dedicated to clinical translation. Enhanced communication between experimental neuroscientists and clinicians, with a shared understanding and common language, will be essential for the success of future research endeavors.

Keywords

Clinical endpoint / translation bottleneck / experimental models / neurological therapy / pharmacological therapy / translation concept

References

[1] Nogueira RG,Jadhav AP,Haussen DC,Bonaf A,Budzik RF,Bhuva P,et al.Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct.N Engl J Med.2018;378:11-21.

[2] Günkan A,Ferreira MY,Vilardo M,Scarcia L,Bocanegra-Becerra JE,Cardoso LJC,et al.Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials.Stroke.2025;56:580-90.

[3] Derfuss T,Mehling M,Papadopoulou A,Bar-Or A,Cohen JA,Kappos L.Advances in oral immunomodulating therapies in relapsing multiple sclerosis.Lancet Neurol.2020;19:336-47.

[4] Pluchino S,Smith JA,Peruzzotti-Jametti L.Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis.Trends Mol Med.2020;26:898-912.

[5] Fox RJ,Bar-Or A,Traboulsee A,Oreja-Guevara C,Giovannoni G,Vermersch PHERCULES Trial Group.Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.N Engl J Med.2025;392:1883-92.

[6] van Dyck CH,Swanson CJ,Aisen P,Bateman RJ,Chen C,Gee M,et al.Lecanemab in Early Alzheimer’s Disease.N Engl J Med.2023;388:9-21.

[7] Mintun MA,Lo AC,Evans CD,Wessels AM,Ardayfio PA,Andersen SW,et al.Donanemab in Early Alzheimer’s Disease.N Engl J Med.2021;384:1691-704.

[8] Benjamin EJ,Muntner P,Alonso A,Bittencourt MS,Callaway CW,Carson AP,et al.American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee.Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.Circulation.2019;139:e56-e528.

[9] Scheltens P,Strooper BD,Kivipelto M,Holstege H,Chételat G,Teunissen CE,et al.Alzheimer’s disease.Lancet.2021;397:1577-90.

[10] Scalfari A,Traboulsee A,Oh J,Airas L,Bittner S,Calabrese M,et al.Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.Ann Neurol.2024;96:826-45.

[11] Hermann DM.Cutting edges in neuroscience to exceed borders.Explor Neurosci.2022;1:1-3.

[12] Tavakoli MR,Lyudchik J,Januszewski M,Vistunou V,Dueñas NA,Vorlaufer J,et al.Light-microscopy-based connectomic reconstruction of mammalian brain tissue.Nature.2025;642:398-410.

[13] Nogales E,Mahamid J.Bridging structural and cell biology with cryo-electron microscopy.Nature.2024;628:47-56.

[14] Rolfes L,Riek-Burchardt M,Pawlitzki M,Minnerup J,Bock S,Schmidt M,et al.Neutrophil granulocytes promote flow stagnation due to dynamic capillary stalls following experimental stroke.Brain Behav Immun.2021;93:322-30.

[15] Neumann J,Riek-Burchardt M,Herz J,Doeppner TR,König R,Hütten H,et al.Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke.Acta Neuropathol.2015;129:259-77.

[16] Woo C,Chang LJ,Lindquist MA,Wager TD.Building better biomarkers: brain models in translational neuroimaging.Nat Neurosci.2017;20:365-77.

[17] Dudzisz K,Wandzik I.Antisense oligonucleotides: A promising advancement in neurodegenerative disease treatment.Eur J Pharmacol.2025;999:177644.

[18] Fumagalli F,Calbi V,Gallo V,Zambon AA,Recupero S,Ciotti F,et al.Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy.N Engl J Med.2025;392:1609-20.

[19] Sun W,Zhang G,Huang JJ,Tao C,Seo MB,Tao HW,et al.Reviving-like prosocial behavior in response to unconscious or dead conspecifics in rodents.Science.2025;387:eadq2677.

[20] Jinek M,Chylinski K,Fonfara I,Hauer M,Doudna JA,Charpentier E.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.Science.2012;337:816-21.

[21] Piwecka M,Rajewsky N,Rybak-Wolf A.Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease.Nat Rev Neurol.2023;19:346-62.

[22] Ghosh S,Tuz AA,Stenzel M,Singh V,Richter M,Soehnlein O,et al.Proteomic Characterization of 1000 Human and Murine Neutrophils Freshly Isolated From Blood and Sites of Sterile Inflammation.Mol Cell Proteomics.2024;23:100858.

[23] Ding J,Ji J,Rabow Z,Shen T,Folz J,Brydges CR,et al.A metabolome atlas of the aging mouse brain.Nat Commun.2021;12:6021.

[24] Park J,Khan S,Yun DH,Ku T,Villa KL,Lee JE,et al.Epitope-preserving magnified analysis of proteome (eMAP).Sci Adv.2021;7:eabf6589.

[25] Luo X,Rechardt A,Sun G,Nejad KK,Yáñez F,Yilmaz B,et al.Large language models surpass human experts in predicting neuroscience results.Nat Hum Behav.2025;9:305-15.

[26] Haupt M,Gerner ST,Bähr M,Doeppner TR.Neuroprotective Strategies for Ischemic Stroke-Future Perspectives.Int J Mol Sci.2023;24:4334.

[27] Savitz SI,Fisher M.Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials.Ann Neurol.2007;61:396-402.

[28] Hermann DM,Bassetti CL.Implications of ATP-binding cassette transporters for brain pharmacotherapies.Trends Pharmacol Sci.2007;28:128-34.

[29] Savitz SI,Baron JC,Fisher MSTAIR X Consortium.Stroke Treatment Academic Industry Roundtable X: Brain Cytoprotection Therapies in the Reperfusion Era.Stroke.2019;50:1026-31.

[30] Hardy J,Selkoe DJ.The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics.Science.2002;297:353-6.

[31] Pluta R.A Look at the Etiology of Alzheimer’s Disease based on the Brain Ischemia Model.Curr Alzheimer Res.2024;21:166-82.

[32] Lecordier S,Pons V,Rivest S,ElAli A.Multifocal Cerebral Microinfarcts Modulate Early Alzheimer’s Disease Pathology in a Sex-Dependent Manner.Front Immunol.2022;12:813536.

[33] Greenberg SM,Bacskai BJ,Hernandez-Guillamon M,Pruzin J,Sperling R,van Veluw SJ.Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways.Nat Rev Neurol.2020;16:30-42.

[34] Heneka MT,van der Flier WM,Jessen F,Hoozemanns J,Thal DR,Boche D,et al.Neuroinflammation in Alzheimer disease.Nat Rev Immunol.2025;25:321-52.

[35] Venegas C,Kumar S,Franklin BS,Dierkes T,Brinkschulte R,Tejera D,et al.Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease.Nature.2017;552:355-61.

[36] van der Flier WM,Heneka MT.Zooming in on brain inflammation in Alzheimer’s disease.Brain.2025;148:1-2.

[37] Itzhaki RF,Lathe R,Balin BJ,Ball MJ,Bearer EL,Braak H,et al.Microbes and Alzheimer’s Disease.J Alzheimers Dis.2016;51:979-84.

[38] Fulop T,Ramassamy C,Lévesque S,Frost EH,Laurent B,Lacombe G,et al.Viruses - a major cause of amyloid deposition in the brain.Expert Rev Neurother.2023;23:775-90.

[39] Moir RD,Lathe R,Tanzi RE.The antimicrobial protection hypothesis of Alzheimer’s disease.Alzheimers Dement.2018;14:1602-14.

[40] Goutman SA,Savelieff MG,Jang D,Hur J,Feldman EL.The amyotrophic lateral sclerosis exposome: recent advances and future directions.Nat Rev Neurol.2023;19:617-34.

[41] Heron CL,MacAskill M,Mason D,Dalrymple-Alford J,Anderson T,Pitcher T,et al.A Multi-Step Model of Parkinson’s Disease Pathogenesis.Mov Disord.2021;36:2530-8.

[42] Srivastava A,Morgan AP,Najarian ML,Sarsani VK,Sigmon JS,Shorter JR,et al.Genomes of the Mouse Collaborative Cross.Genetics.2017;206:537-56.

[43] Iraqi FA,Churchill G,Mott R.The Collaborative Cross, developing a resource for mammalian systems genetics: a status report of the Wellcome Trust cohort.Mamm Genome.2008;19:379-81.

[44] Llovera G,Langhauser F,Cainzos SI,Hoppen M,Abberger H,Yusuf AM,et al.Stroke of Consistency: Streamlining Multicenter Protocols for Enhanced Reproducibility of Infarct Volumes in Preclinical Stroke Research.Stroke.2024;55:2522-7.

[45] Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development.Stroke.1999;30:2752-8.

[46] Fisher M,Feuerstein G,Howells DW,Hurn PD,Kent TA,Savitz SI,et al.STAIR Group.Update of the stroke therapy academic industry roundtable preclinical recommendations.Stroke.2009;40:2244-50.

[47] Cortese I,Reich DS,Nath A.Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.Nat Rev Neurol.2021;17:37-51.

[48] Hermann DM,Bassetti CL,Marx U,Audoli-Inthavong M,Chabriat H.Refining endpoints for stroke recovery trials.Lancet Neurol.2020;19:381-2.

[49] Franchignoni F,Mandrioli J,Giordano A,Ferro SERRALS Group.A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements.Amyotroph Lateral Scler Frontotemporal Degener.2015;16:331-7.

[50] Goodkin DE,Cookfair D,Wende K,Bourdette D,Pullicino P,Scherokman B,et al.Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group.Neurology.1992;42:859-63.

[51] Martínez-Martín P,Gil-Nagel A,Gracia LM,Gómez JB,Martínez-Sarriés J,Bermejo F.Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.Mov Disord.1994;9:76-83.

[52] Broderick JP,Adeoye O,Elm J.Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials.Stroke.2017;48:2007-12.

[53] Donner E,Devinsky O,Friedman D.Wearable Digital Health Technology for Epilepsy.N Engl J Med.2024;390:736-45.

[54] Werner P,Saur D,Zeisig V,Ettrich B,Patt M,Sattler B,et al.Simultaneous PET/MRI in stroke: a case series.J Cereb Blood Flow Metab.2015;35:1421-5.

[55] Pluta R.Neuroinflammation in the Post-Ischemic Brain in the Presence of Amyloid and Tau Protein.Discov Med.2025;37:1-18.

[56] Pearce L,Galán-Arriola C,Bell RM,Carr RD,Cunningham J,Davidson SM,et al.Inter-organ communication: pathways and targets to cardioprotection and neuro-protection. A report from the 12th Hatter Cardiovascular Institute workshop.Basic Res Cardiol.2025;120:287-99.

[57] Pluta R,Januszewski S.Gut microbiota neurotransmitters: influence on risk and outcome of ischemic stroke.Neural Regen Res.2023;18:1707-8.

[58] Sharkey KA,Mawe GM.The enteric nervous system.Physiol Rev.2023;103:1487-564.

[59] Niesler B,Kuerten S,Demir IE,Schäfer K.Disorders of the enteric nervous system - a holistic view.Nat Rev Gastroenterol Hepatol.2021;18:393-410.

[60] Yin D,Wang C,Singh V,Tuz AA,Doeppner TR,Gunzer M,et al.Delayed DNase-I Administration but Not Gasdermin-D Inhibition Induces Hemorrhagic Transformation After Transient Focal Cerebral Ischemia in Mice.Stroke.2024;55:e297-e299.

[61] Ehrenreich H,Weissenborn K,Prange H,Schneider D,Weimar C,Wartenberg K,et al.EPO Stroke Trial Group.Recombinant human erythropoietin in the treatment of acute ischemic stroke.Stroke.2009;40:e647-56.

[62] Zechariah A,ElAli A,Hermann DM.Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice.Stroke.2010;41:1008-12.

[63] Bassotti G,Battaglia E.Considerations for laxatives in terms of their interactions with other drugs.Expert Opin Drug Metab Toxicol.2023;19:121-3.

[64] Lapchak PA,Zhang JH,Noble-Haeusslein LJ.RIGOR guidelines: escalating STAIR and STEPS for effective translational research.Transl Stroke Res.2013;4:279-85.

[65] Trenité DK,Löscher W.The human photosensitive epilepsy model for clinical proof-of-principle trials of novel antiseizure medications. 1. Use of the EEG in drug development and characteristics of the model.Epilepsia.2025;[Epub ahead of print]

[66] Huntemann N,Rolfes L,Pawlitzki M,Ruck T,Pfeuffer S,Wiendl H,et al.Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.Drugs.2021;81:1031-63.

[67] Tarkowska A,Furmaga-Jabłońska W,Bogucki J,Kocki J,Pluta R.Preservation of Biomarkers Associated with Alzheimer’s Disease (Amyloid Peptides 1-38, 1-40, 1-42, Tau Protein, Beclin 1) in the Blood of Neonates after Perinatal Asphyxia.Int J Mol Sci.2023;24:13292.

[68] Hermann DM,Giebel B.Extracellular vesicles: multiple signaling capabilities and translation into promising therapeutic targets to promote neuronal plasticity.Neural Regen Res.2025;20:3521-2.

[69] Vogelgsang J,Hansen N,Stark M,Wagner M,Klafki H,Morgado BM,et al.Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer’s disease.Alzheimers Dement.2024;20:5132-42.

[70] Zucchi E,Bonetto V,Sorarù G,Martinelli I,Parchi P,Liguori R,et al.Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers.Mol Neurodegener.2020;15:58.

[71] Freedman MS,Abdelhak A,Bhutani MK,Freeman J,Gnanapavan S,Hussain S,et al.The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review.J Neurol.2025;272:400.

[72] Miller TM,Cudkowicz ME,Genge A,Shaw PJ,Sobue G,Bucelli RC,et al.VALOR and OLE Working Group.Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.N Engl J Med.2022;387:1099-10.

[73] Rezayof A,Ghasemzadeh Z,Kouhkan F.microRNAs Mediate Signaling Pathways in Alzheimer’s Disease: Biomarkers and Therapeutic Targets. In: Kateb B,Heiss JD,Yu JS,Hsieh M. editors.The Textbook of Nanoneuroscience and Nanoneurosurgery.Cham:Springer2024.pp. 657–86.

[74] Cai Z,Zhong Q,Feng Y,Wang Q,Zhang Z,Wei C,et al.Non-invasive mapping of brown adipose tissue activity with magnetic resonance imaging.Nat Metab.2024;6:1367-79.

[75] Wang K,Huang J,Ju L,Xu S,Gullapalli RP,Liang Y,et al.Creatine mapping of the brain at 3T by CEST MRI.Magn Reson Med.2024;91:51-60.

[76] Ossenkoppele R,Binette AP,Groot C,Smith R,Strandberg O,Palmqvist S,et al.Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.Nat Med.2022;28:2381-7.

[77] Lo RY.To Trust or Not to Trust? ICD-Coded Diagnosis of Parkinson’s Disease.Mov Disord.2025;40:181-3.

[78] Mehdiyeva A,Kaasinen V,Heervä E,Sipilä JOT.Impact of Parkinson’s disease diagnosis validity on the association with cancer: A systematic review and meta-analysis.Parkinsonism Relat Disord.2025;135:107846.

[79] Höfler M.The effect of misclassification on the estimation of association: a review.Int J Methods Psychiatr Res.2005;14:92-101.

[80] Mattioli F,Maglianella V,D’Antonio S,Trimarco E,Caligiore D.Non-invasive brain stimulation for patients and healthy subjects: Current challenges and future perspectives.J Neurol Sci.2024;456:122825.

[81] Pennisi M,Lanza G,Cantone M,Ricceri R,Ferri R,D’Agate CC,et al.Cortical involvement in celiac disease before and after long-term gluten-free diet: A Transcranial Magnetic Stimulation study.PLoS One.2017;12:e0177560.

[82] Perez FP,Walker B,Morisaki J,Kanakri H,Rizkalla M.Neurostimulation devices to treat Alzheimer’s disease.Explor Neurosci.2025;4:100674.

[83] Holston EC.Raw resting-state electroencephalogram biomarker emerges as an indicator of Alzheimer’s disease over a two-year period.Explor Neurosci.2025;4:100677.

[84] Mulumba J,Duan R,Luo B,Wu J,Sulaiman M,Wang F,et al.The role of neuroimaging in Alzheimer’s disease: implications for the diagnosis, monitoring disease progression, and treatment.Explor Neurosci.2025;4:100675.

[85] Krauss JK,Lipsman N,Aziz T,Boutet A,Brown P,Chang JW,et al.Technology of deep brain stimulation: current status and future directions.Nat Rev Neurol.2021;17:75-87.

[86] Tanner CM,Ostrem JL.Parkinson’s Disease.N Engl J Med.2024;391:442-52.

[87] Toth J,Kurtin DL,Brosnan M,Arvaneh M.Opportunities and obstacles in non-invasive brain stimulation.Front Hum Neurosci.2024;18:1385427.

[88] Cantone M,Fisicaro F,Ferri R,Bella R,Pennisi G,Lanza G,et al.Sex differences in mild vascular cognitive impairment: A multimodal transcranial magnetic stimulation study.PLoS One.2023;18:e0282751.

[89] Shafiei SB,Shadpour S,Pangburn B,Bentley-McLachlan M,de Leon-Casasola O.Pain classification using functional near infrared spectroscopy and assessment of virtual reality effects in cancer pain management.Sci Rep.2025;15:8954.

[90] Stammler B,Flammer K,Schuster T,Lambert M,Neumann O,Lux M,et al.Spatial Neglect Therapy With the Augmented Reality App “Negami” for Active Exploration Training: A Randomized Controlled Trial on 20 Stroke Patients With Spatial Neglect.Arch Phys Med Rehabil.2023;104:1987-94.

[91] Nicoletti VG,Fisicaro F,Aguglia E,Bella R,Calcagno D,Cantone M,et al.Challenging the Pleiotropic Effects of Repetitive Transcranial Magnetic Stimulation in Geriatric Depression: A Multimodal Case Series Study.Biomedicines.2023;11:958.

[92] Boes AD,Kelly MS,Trapp NT,Stern AP,Press DZ,Pascual-Leone A.Noninvasive Brain Stimulation: Challenges and Opportunities for a New Clinical Specialty.J Neuropsychiatry Clin Neurosci.2018;30:173-9.

[93] Desarkar P,Vicario CM,Soltanlou M.Non-invasive brain stimulation in research and therapy.Sci Rep.2024;14:29334.

[94] Huang Y,Gan Y,Yang L,Cheng W,Yu J.Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment.Biol Psychiatry.2024;95:992-1005.

[95] Choi K,Lee J,Kim G,Lim Y,Kang HJ.Recovery of synaptic loss and depressive-like behavior induced by GATA1 through blocking of the neuroinflammatory response.Front Cell Neurosci.2024;18:1369951.

[96] Wang C,Giebel B,Hermann DM.Neuroprotective and neurorestorative actions of mesenchymal stromal cell-derived small extracellular vesicles in the ischemic brain.Explor Neurosci.2022;1:61-74.

[97] Dzyubenko E,Hermann DM.Role of glia and extracellular matrix in controlling neuroplasticity in the central nervous system.Semin Immunopathol.2023;45:377-87.

[98] Hermann DM,Peruzzotti-Jametti L,Giebel B,Pluchino S.Extracellular vesicles set the stage for brain plasticity and recovery by multimodal signalling.Brain.2024;147:372-89.

[99] Brown GC.Cell death by phagocytosis.Nat Rev Immunol.2024;24:91-102.

[100] Fontana L,Partridge L,Longo VD.Extending healthy life span--from yeast to humans.Science.2010;328:321-6.

[101] Bassotti G,Villanacci V.Can “functional” constipation be considered as a form of enteric neuro-gliopathy?Glia.2011;59:345-50.

[102] Bassotti G,Villanacci V,Antonelli E,Morelli A,Salerni B.Enteric glial cells: new players in gastrointestinal motility?Lab Invest.2007;87:628-32.